B-cell depletion is protective against anti-AAV capsid immune response: a human subject case study
Gene therapy strategies for congenital myopathies may require repeat administration of adeno-associated viral (AAV) vectors due to aspects of the clinical application, such as: (i) administration of doses below therapeutic efficacy in patients enrolled in early phase clinical trials; (ii) progressiv...
Main Authors: | M Corti, ME Elder, DJ Falk, L Lawson, BK Smith, S Nayak, TJ Conlon, N Clément, K Erger, E Lavassani, MM Green, PA Doerfler, RW Herzog, BJ Byrne |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2014-01-01
|
Series: | Molecular Therapy: Methods & Clinical Development |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2329050116301000 |
Similar Items
-
AAV capsid CD8+ T-cell epitopes are highly conserved across AAV serotypes
by: Daniel J Hui, et al.
Published: (2015-01-01) -
Capsid Modifications for Targeting and Improving the Efficacy of AAV Vectors
by: Hildegard Büning, et al.
Published: (2019-03-01) -
Novel AAV capsids for intravitreal gene therapy of photoreceptor disorders
by: Marina Pavlou, et al.
Published: (2021-04-01) -
Cross-Packaging and Capsid Mosaic Formation in Multiplexed AAV Libraries
by: Pauline F. Schmit, et al.
Published: (2020-06-01) -
Site-Specific N-Glycosylation on the AAV8 Capsid Protein
by: Arya Aloor, et al.
Published: (2018-11-01)